Carrollton, TXNCT07209475Now EnrollingIRB Ready

Diabetic Foot Ulcer (DFU) Clinical Trial in Carrollton, TX

Access cutting-edge diabetic foot ulcer (dfu) treatment through this clinical trial at a research site in Carrollton. Study-provided care at no cost to qualified participants.

Sponsored by Royal Biologics

Quick Self-Assessment

See if you qualify for this Carrollton location

Preparing your pre-screening questions…

Expert Care in Carrollton

Access diabetic foot ulcer (dfu) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diabetic foot ulcer (dfu) treatment provided free

Apply for This Carrollton Location

Check if you qualify for this diabetic foot ulcer (dfu) clinical trial in Carrollton, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Carrollton

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Carrollton site if eligible
  4. 4Begin participation

About This Diabetic Foot Ulcer (DFU) Study in Carrollton

This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.

Sponsor: Royal Biologics

Who Can Participate

Inclusion Criteria

Potential subjects are required to meet all the following criteria for enrollment into the study and subsequent randomization.
The potential subject is 18 years of age or older. At least 50% of the enrolled population must be \> 65 years of age.
The potential subject has a history of Type I or Type II Diabetes Mellitus requiring treatment by a physician with either oral medications and/or insulin replacement therapy.
Potential subjects have an ulcer characterized by the following:
Presence of a diabetic foot ulcer Wagner 1 or 2 grade at the first screening visit on any aspect of the foot, provided it is at or below the aspect of the medial malleolus. \[NOTE: If two or more DFUs are present with the same grade, the index ulcer is the largest ulcer and the only one evaluated in the study. Index ulcer must be more than 5 cm distant apart.\]
A diabetic foot ulcer present for greater than 4 weeks (documented in the medical record) but less than 12 months duration if being treated with active SOC.
Objectively, less than 20% healing in the two-week screening period prior to randomization.
Study ulcer is a minimum of 1.0cm2 and a maximum of 25 cm2 post-debridement at first treatment visit.
Index ulcer and/or index ulcer limb may have had prior infection, but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines Grade level 1
The subject is able and willing to follow the protocol requirements.
Subject has signed informed consent. Adequate circulation to the affected foot as demonstrated by a dorsum transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg; an ABI between 0.7 and ≤ 1.3, or TBI of \>6 within 3 months of the first Screening Visit. 10\. Negative pregnancy test for females of childbearing potential (e.g., not post- menopausal for at least one year or surgically sterile). Females of childbearing potential must be willing to use acceptable methods of contraception (birth control methods, barriers, or abstinence) starting at Screening and continuing through the duration of their study participation. 11\. The index ulcer has been offloaded with protocol defined offloading device throughout the study run-in period for at least 14 days prior to randomization (Run-in period defined as Screening through TV1/Randomization). 12\. The index ulcer has a clean base and is free of necrotic debris at time of placement of treatment product.

Exclusion Criteria

The Subject has a known life expectancy of \< 1 year.
Index ulcer has been present for \>1 year.
Patient does not have adequate 2-week historical data demonstrating \< 20% area reduction.
Subject is unable to comply with offloading device.
Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence to medical treatment.
Subject has ulcers that are completely necrotic or fibrotic tissue
Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia.
Subject currently being treated for an active malignant disease
or subjects with history of malignancy within the ulcer.
The Subject has other concurrent conditions that in the opinion of the Principal Investigator may compromise subject safety.
Known contraindications to amniotic tissue membranes or known allergies to any of the Amnio-Maxx components.
Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study.
Index ulcer has reduced in area by 20% or more after 2 weeks of standard of care from the first screening visit (S1) to the TV1/randomization visit.
Subject is pregnant or breastfeeding.
Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids
\>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 30 days prior to randomization visit or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit. \-

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Carrollton?

Yes, this clinical trial (NCT07209475) has an active research site in Carrollton, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diabetic Foot Ulcer (DFU) Treatment Options in Carrollton, TX

If you're searching for diabetic foot ulcer (dfu) treatment options in Carrollton, TX, this clinical trial (NCT07209475) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Carrollton research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diabetic foot ulcer (dfu) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diabetic foot ulcer (dfu) clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Carrollton, TX

See all essential tremor clinical trials recruiting in Carrollton — not just this study.

Browse Essential Tremor Trials in Carrollton →

Browse More Trials by Condition

Essential Tremor TrialsType 2 Diabetes TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Carrollton?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Carrollton, TX